Business Context and Reporting Period
This Form 8-K filing by Aclaris Therapeutics, Inc. (ACRS) reports events occurring on June 6, 2019, specifically the company's 2019 Annual Meeting of Stockholders and a change in board leadership. The company is incorporated in Delaware and trades on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Board Resignation: Stephen Tullman resigned as Chairman of the Board and as a director, effective June 7, 2019.
- Annual Meeting Results: The company held its annual meeting with 85.46% of outstanding shares present or represented by proxy.
Outlook, Risks, and Management Commentary
The filing details the voting outcomes for two proposals:
- Proposal 1 (Election of Directors): Three nominees were elected to serve until the 2022 annual meeting.
- Neal Walker: 26,814,764 votes for; 4,976,631 withheld.
- William Humphries: 22,209,532 votes for; 9,581,863 withheld.
- Andrew Schiff: 26,766,604 votes for; 5,024,791 withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Votes For: 35,198,683
- Votes Against: 69,673
- Abstained: 3,858
No specific guidance, risk factors, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the composition of the new Board of Directors following Stephen Tullman's resignation.
- Review the definitive proxy statement filed on April 25, 2019, for detailed background on the director nominees and auditor appointment.
- Check subsequent filings for the appointment of a new Chairman of the Board.